ASCO-SITC MERECA Podium Presentation

  • 19:44

A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma

Magnus Lindskog, MD, PhD; Uppsala University Hospital, Sweden

ASCO-SITC Podium Presentation


Notice: Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /home/i/immunicu/www/wp-includes/functions.php on line 4805

Comments are closed.